Organised by SHC
For 2025 ONLY:
Asian HBV/HDV Endpoints Consensus Meeting
For Scientists, Clinician Scientists and
Pharmacists and Industry Experts
22 to 24 August 2025
8:30 am to 5:00 pm (SGT)
Asian HBV/HDV Endpoints Consensus Meeting
REGISTRATION FOR The 1st Asian Hepatology Summit includes Asian HBV/HDV Endpoints Consensus Meeting.
HBV Cure is now becoming a reality with new drugs being tested in phase 3 clinical trials to achieve HBV Cure. This will bring hope to 257 Million Chronic Hepatitis B patients globally but exactly what is Hepatitis B Cure? Patients, doctors, scientists and pharmaceutical companies need to understand the disease, the new treatments and reach consensus on Hepatitis B Cure. HDV is emerging as an important disease for which therapy is rapidly evolving
This will be a three (3) day meeting focusing on establishing consensus as well as examining challenges and opportunities in Hepatitis B and Hepatitis D endpoints, from the clinical, scientific and public health perspectives in Asia.
• The Objectives are:
> Endpoints standardization and consensus-building.
> Novel treatments likely to achieve HBV Cure.
> Blood and liver biomarkers for HBV Cure.
> Definitions and Treatments for HDV Cure.
REGISTER HERE for The 1st Asian Hepatology Summit which includes Asian HBV/HDV Endpoints Consensus Meeting
To access SHC e-Resources REGISTER HERE or LOG IN (if you have previously registered for SHC)
Meet Our Experts
Coming Soon..
Asian HBV/HDV Endpoints Consensus Meeting Scientific Programme
in Ballroom 3 & 4
| Friday, 22 August 2025 | |
|---|---|
| Asian HBV/HDV Endpoints Consensus Meeting | Session 1 – Opening lecture: A need for Asian Consensus HBV Endpoint meeting – Overview of HBV virology and HBV immunology |
| Session 2 – Revisiting terminology for HBV endpoints for patients, functional cure, occult HBV infection, virological cure and complete cure |
|
| Session 3 – Novel biomarkers in clinical trials and clinical practice |
|
| Saturday, 23 August 2025 | |
|---|---|
| Asian HBV/HDV Endpoints Consensus Meeting | Session 4 – Existing treatment strategies including strategies for HBV cure |
| Session 5 – ALT flares |
|
| Session 6 – The role of evaluating the liver microenvironment in clinical trials of CHB |
|
| Sunday, 24 August 2025 | |
|---|---|
| Asian HBV/HDV Endpoints Consensus Meeting | Session 7 – Delta Hepatitis – Delta Hepatitis endpoints |
| Session 8 – Delta Hepatitis existing therapy – Delta Hepatitis upcoming therapy |
|
August, 2026
22
| Programme | Time (SGT) |
|---|---|
| Session 1: (Chair) Overview |
|
| Opening lecture: A need for Asian Consensus HBV Endpoint meeting Prof. Lim Seng Gee View Bio |
8.40 – 8.45 |
| a. Scope of the meeting and agenda items Prof. Lim Seng Gee View Bio |
8.45 – 8.50 |
| Session 2 Consensus Statement 1: Consensus On Cure Definitions Revisiting terminology for HBV endpoints for patients and clinical trials of treatments of CHB: partial cure, functional cure, occult HBV infection, virological cure and complete cure Chairs Chairs: Prof. Geoff Dusheiko View Bio & Dr. Rajneesh Kumar |
|
| a. HCC risk and HBV DNA vs HBsAg Levels Prof. Young-Suk Lim View Bio |
8.50 – 9.10 |
| b. Partial cure is it a useful endpoint? Prof. Maria Buti FerretView Bio |
9.10 – 9.30 |
| c. Definitions and outcomes of Occult HBV infection Prof. Massimo Levrero View Bio |
9.30 – 9.50 |
| d. Viral integration: what is important? New integrations or integration burden Prof. Thomas Tu View Bio |
9.50 – 10.10 |
| e. From functional cure to virological cure Prof. Lim Seng Gee View Bio |
10.10 – 10.30 |
| f. Consolidating nomenclature forum Panel members including Mr. Dee Lee,View Bio Prof. Philippa EasterbrookView Bio & Prof. Veronica Miller,View Bio Prof. Thomas Tu View Bio |
10.30 – 10.50 |
| g. Discussion | 10.50 – 11.10 |
| Tea Break | 11.10 – 11.30 |
| Session 3: Consensus Statement 2: Biomarkers In Clinical Studies Of CHB Chairs: Prof. Henry Chan View Bio &, Prof. Thomas Tu View Bio |
|
| (1) The role of evaluating the liver microenvironment in clinical trials of CHB | |
| a. What to measure in the liver microenvironment (Immunology) Dr. Nina LeBert View Bio |
11.30 – 11.50 |
| b. What to measure in the liver microenvironment (Virology) Prof. Massimo Levrero View Bio |
11.50 – 12.10 |
| c. HBV integration and its loss during functional cure Prof. Thomas Tu View Bio |
12.10 – 12.30 |
| d. FNA vs LBx and the utility of liver tissue in clinical trials Prof. Geoff Dusheiko View Bio |
12.30 – 12.50 |
| e. Discussion | 12.50 – 13.10 |
| Lunch & Poster Viewing: | |
| a. Liver diseases (other than Viral Hepatitis) | 13.10 – 13.30 |
| b. Viral Hepatitis | 13.30 – 14.10 |
| Session 3: (Continuation) Consensus Statement 2: Biomarkers In Clinical Studies |
|
| (2) Novel biomarkers in clinical trials and clinical practice | |
| a. Spectrum of HBV biomarkers and virological pathways Prof. Massimo Levrero View Bio |
14.10 – 14.30 |
| b. Utility of novel biomarkers in CHB management Dr. Lung Yi Mak View Bio |
14.30 – 14.50 |
| c. Discussion | 14.50 – 15.10 |
| Tea Break | 15.10 – 15.30 |
| Session 4: (Chair) Consensus Statement 3: The Role Of Existing Treatment Strategies In Functional Cure Existing treatment strategies including strategies for HBV cure Chairs: Prof. Maria Buti Ferret View Bio & Prof. Khin Maung Win |
|
| a. Is NUC therapy needed for new trials of CHB for functional cure? Prof. Norah Terrault View Bio |
15.30 – 15.50 |
| b. Long term outcomes of NUC therapy Prof. Wei Lai View Bio |
15.50 – 16.10 |
| c. The use of Peginterferon in CHB functional cure Prof. Lim Seng Gee View Bio |
16.10 – 16.30 |
| d. Stopping NUC therapy Prof. Henry Chan View Bio |
16.30 – 16.50 |
| e. Discussion | 16.50 – 17.10 |
| End of Day 1 | |
August, 2026
23
| Programme | Time (SGT) |
|---|---|
| Session 5: (Chair) Consensus Statement 4: Novel Therapies For Functional Cure Novel therapeutics leading to functional cure – controversies Chair: Prof. Massimo Levrero View Bio & Prof. Seng Gee Lim View Bio |
|
| a. SCG101 HBV-specific TCR-T cell therapy demonstrates dual antiviral and antitumor activities, achieving HBV clearance in liver biopsies and functional cure in HBV-related hepatocellular carcinoma patients Dr. Karin Wisskirchen View Bio |
8.00 – 8.20 |
| b. ASO RNA therapeutics state of the art Prof. MF Yuen View Bio |
8.20 – 8.40 |
| c. RNA interference combination therapy Dr. Lung Yi Mak View Bio |
8.40 – 9.00 |
| d. Current Immunotherapy current prospects for functional cure Prof. Antonio Bertoletti View Bio |
9.00 – 9.20 |
| e. Gene therapy and prospects for HBV complete cure Prof. Ed Gane View Bio |
9.20 – 9.40 |
| f. Discussion | 9.40 – 10.00 |
| Morning Tea Symposium sponsored by Roche – Live in Ballroom 1 & 2 – Live Stream in Ballroom 3 & 4 Innovating Hepatocellular Carcinoma Surveillance with Biomarker-based Algorithm Prof. Henry Chan View Bio |
10.00 – 10.50 |
| Session 6: Consensus Statement 5: Diagnosis And Management Of ALT Flares ALT flares Chairs: Prof. Ed Gane View Bio & Dr. Edhel Tripon |
|
| a. Definitions of ALT flares and natural history and prediction of decompensation Prof. Teerha Piratvisuth View Bio |
10.50 – 11.10 |
| b. ALT flares associated with novel therapies: risks and benefits Prof. MF Yuen View Bio |
11.10 – 11.30 |
| c. Management of ALT flares, beyond antiviral therapy pros and cons Prof. Lim Seng Gee View Bio |
11.30 – 11.50 |
| d. Discussion | 11.50 – 12.10 |
| Lunch symposium sponsored by GSK – Live in Ballroom 3 & 4 – Live Stream in Ballroom 1 & 2 Destination functional cure in CHB: What success looks like? |
|
| a. Welcome and Introduction Prof. Lim Seng Gee View Bio |
12.20 – 12.25 |
| b. Lighting the road ahead: Understanding the burden of CHB & importance of Functional cure Prof. Lim Seng Gee View Bio |
12.25 – 12.40 |
| c. Vital components of Functional Cure – Targeting DNA, reducing HBsAg, and stimulating the immune system Prof. Man Fung Yuen View Bio |
12.40 – 12.55 |
| d. Navigating the path forward: Old and new strategies to achieve Functional Cure Prof. Edward Gane View Bio |
12.55 – 13.10 |
| e. Discussions and Q&A Panel moderated by Prof. Lim Seng Gee View Bio |
13.10 – 13.20 |
| Session 7: Delta Hepatitis: Consensus Statement 6: Chair: Prof. Khin Maung Win & Prof. Norah Terrault View Bio |
|
| (1) The burden of HDV in Asia and endpoints of Delta cure | |
| a. Delta natural history Prof. Junqi Niu View Bio |
13.40 – 14.00 |
| b. Asian epidemiology and diagnosis of Delta infection Prof. Saeed Hamid View Bio |
14.00 – 14.20 |
| (2) Delta Hepatitis endpoints (Con’t) | |
| a. HBV and HDV biomarkers for Delta management Prof. Pietro Lampertico View Bio |
14.20 – 14.40 |
| b. What is the appropriate endpoints for Delta cure Prof. Geoff Dusheiko View Bio |
14.40 – 15.00 |
| c. Discussion | 15.00 – 15.20 |
| Afternoon tea symposium sponsored by Novo Nordisk – Live in Ballroom 1 & 2 – Live Stream in Ballroom 3 & 4 From Obesity to Liver disease: Redefining treatment paradigms through metabolic intervention Dr. Rahul Kumar View Bio |
15.20 – 16.10 |
| Session 8: Delta Hepatitis existing and emerging therapy Consensus Statement 7: Management Of HDV In Asia Chair: Prof. Wei Lai View Bio & Prof. Norah Terrault View Bio |
|
| a. Bulevirtide (BLV) monotherapy or in combination Prof. Pietro Lampertico View Bio |
16.10 – 16.30 |
| b. Other Anti HDV therapeutics: current and novel therapies Prof. Saeed Hamid View Bio |
16.30 – 16.50 |
| c. Discussion | 16.50 – 17.10 |
| End of Day 2 | |
August, 2026
24
| Programme | Time (SGT) |
|---|---|
| Session 9: Consensus Statement Session (Closed Door Meeting) In Ballroom 1 Chair: Prof. Lim Seng Gee View Bio |
|
| a. Discussions on Consensus Statements | 8.30 – 10.00 |
| Tea Break | 10.00 – 10.30 |
| b. Discussions on Consensus Statements | 10.30 – 12.30 |
| HCV Elimination Lunch Symposium Sponsored by Gilead – Live in Ballroom 3 & 4 – Live Stream in Ballroom 1 & 2 Moderator: Prof. Lim Seng Gee View Bio |
12.30 – 14.00 |
| a. Charting the path to HCV elimination in South East Asia – overview of national plans, screening targets, integration into primary care towards WHO 2030 goal Dr. John Ward View Bio |
12.45 – 13.05 |
| b. From diagnosis to cure: scale up test and treat and practical models to decentralise HCV care Prof. Philippa Easterbrook View Bio |
13.05 – 13.25 |
| c. Closing the gaps: Advancing Singapore towards HCV elimination Prof. Wong Chen Seong View Bio |
13.25 – 13.45 |
| d. Q&A | |
| Session 10: HBV/HDV Elimination Forum Chair: Prof. Saeed Hamid View Bio & Prof. Philippa Easterbrook View Bio |
|
| HBV elimination: The greatest achievement,. The greatest challenge Dr. John Ward View Bio |
14.00 – 14.20 |
| What practical steps can we take to achieve WHO 2030 goals Prof. Philippa Easterbrook (UCL London) View Bio |
14.20 – 14.40 |
| What is the status, challenges and solutions for HDV elimination in Asia Prof. Saeed Hamid View Bio |
14.40 – 15.00 |
| Discussion forum | 15.00 – 15.20 |
| Tea break | 15.20 – 15.40 |
| What roles can patients take in HBV Elimination and the challenges Mr. Dee Lee View Bio |
15.40 – 16.00 |
| The role of global collaboration, Trials, and stakeholders How can NGOs support the mission of HBV/HDV elimination Prof. Veronica Miller View Bio |
16.00 – 16.20 |
| Discussion forum | 16.20 – 16.40 |
| Close of Day 3 and Conference | 16.50 – 17.00 |
Who Should Attend?
Asian HBV/HDV Endpoints Consensus Meeting is designed for Clinicians, Scientists (virologists, Immunologists), Pharma Executives and Industry Experts.
Call for Abstracts
Submission Deadline: 27 June 2025
We invite all interested parties to present their research papers. Click on below Abstracts and Posters for further information.
Abstracts will be reviewed by the Abstract Selection Committee and accepted submissions will be posted on Abstract & Poster Gallery in our website and in the Poster Hall.